 Mary Demoruelle
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 64 | 2025 | 1167 | 10.720 |
Why?
| | Anti-Citrullinated Protein Antibodies | 19 | 2025 | 115 | 4.710 |
Why?
| | Autoantibodies | 35 | 2025 | 1496 | 4.480 |
Why?
| | Lung Diseases, Interstitial | 14 | 2025 | 638 | 3.430 |
Why?
| | Connective Tissue Diseases | 5 | 2024 | 84 | 2.930 |
Why?
| | Sputum | 5 | 2025 | 311 | 2.500 |
Why?
| | Immunoglobulin A | 10 | 2023 | 211 | 2.340 |
Why?
| | Extracellular Traps | 4 | 2023 | 53 | 2.190 |
Why?
| | Peptides, Cyclic | 13 | 2023 | 259 | 1.980 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2023 | 657 | 1.940 |
Why?
| | Immunity, Mucosal | 4 | 2020 | 97 | 1.740 |
Why?
| | Autoimmunity | 11 | 2025 | 908 | 1.630 |
Why?
| | Rheumatoid Factor | 12 | 2025 | 175 | 0.970 |
Why?
| | Pulmonary Fibrosis | 2 | 2025 | 402 | 0.890 |
Why?
| | Infertility, Female | 1 | 2024 | 108 | 0.850 |
Why?
| | Fertility | 1 | 2024 | 160 | 0.830 |
Why?
| | Antiphospholipid Syndrome | 1 | 2023 | 34 | 0.810 |
Why?
| | Citrullination | 3 | 2020 | 13 | 0.790 |
Why?
| | Bronchial Diseases | 2 | 2013 | 37 | 0.780 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 480 | 0.770 |
Why?
| | Citrulline | 3 | 2020 | 45 | 0.700 |
Why?
| | Microbiota | 3 | 2021 | 762 | 0.670 |
Why?
| | Humans | 72 | 2025 | 137585 | 0.660 |
Why?
| | Pregnancy Complications | 1 | 2024 | 527 | 0.630 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2022 | 242 | 0.620 |
Why?
| | Inflammation | 5 | 2022 | 2837 | 0.620 |
Why?
| | Autoantigens | 4 | 2022 | 430 | 0.570 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2023 | 852 | 0.570 |
Why?
| | Lung | 8 | 2023 | 4060 | 0.530 |
Why?
| | Pedigree | 2 | 2020 | 514 | 0.530 |
Why?
| | Antirheumatic Agents | 2 | 2024 | 293 | 0.510 |
Why?
| | Lung Diseases | 2 | 2013 | 767 | 0.490 |
Why?
| | Middle Aged | 33 | 2025 | 33479 | 0.450 |
Why?
| | Pneumonia | 1 | 2020 | 639 | 0.430 |
Why?
| | Aged | 22 | 2025 | 23961 | 0.420 |
Why?
| | Female | 40 | 2025 | 73304 | 0.400 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 89 | 0.380 |
Why?
| | Male | 37 | 2025 | 67762 | 0.370 |
Why?
| | Arthritis | 1 | 2012 | 95 | 0.370 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 116 | 0.370 |
Why?
| | Respiration Disorders | 2 | 2022 | 77 | 0.360 |
Why?
| | Mucin-5B | 2 | 2025 | 224 | 0.360 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.360 |
Why?
| | Case-Control Studies | 10 | 2025 | 3556 | 0.350 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 140 | 0.350 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 460 | 0.330 |
Why?
| | Risk Factors | 15 | 2022 | 10388 | 0.330 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 318 | 0.310 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 600 | 0.300 |
Why?
| | Adult | 25 | 2025 | 37929 | 0.300 |
Why?
| | Prospective Studies | 13 | 2025 | 7604 | 0.290 |
Why?
| | Histones | 3 | 2021 | 636 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 2691 | 0.270 |
Why?
| | Disease Progression | 8 | 2024 | 2757 | 0.270 |
Why?
| | Epitopes | 5 | 2023 | 479 | 0.260 |
Why?
| | Neutrophils | 2 | 2023 | 1238 | 0.260 |
Why?
| | Biomarkers | 6 | 2025 | 4149 | 0.250 |
Why?
| | Chlamydia trachomatis | 1 | 2025 | 49 | 0.230 |
Why?
| | Intestines | 2 | 2021 | 357 | 0.230 |
Why?
| | Chlamydia Infections | 1 | 2025 | 75 | 0.210 |
Why?
| | Adenylate Kinase | 1 | 2023 | 26 | 0.210 |
Why?
| | Scleroderma, Systemic | 1 | 2024 | 122 | 0.210 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 137 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2426 | 0.210 |
Why?
| | Antibody Formation | 3 | 2022 | 298 | 0.210 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 228 | 0.200 |
Why?
| | Incidence | 5 | 2021 | 2804 | 0.190 |
Why?
| | Immunosuppressive Agents | 2 | 2024 | 890 | 0.190 |
Why?
| | Hydrolases | 1 | 2021 | 48 | 0.180 |
Why?
| | Dysbiosis | 2 | 2020 | 181 | 0.170 |
Why?
| | Neutrophil Activation | 1 | 2021 | 80 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 99 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 98 | 0.170 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.170 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.170 |
Why?
| | Vimentin | 1 | 2020 | 52 | 0.170 |
Why?
| | Early Diagnosis | 3 | 2022 | 242 | 0.170 |
Why?
| | Milk Proteins | 1 | 2020 | 34 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 192 | 0.160 |
Why?
| | Muramidase | 1 | 2020 | 78 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 185 | 0.160 |
Why?
| | Malondialdehyde | 1 | 2019 | 29 | 0.160 |
Why?
| | Bacteriophages | 1 | 2021 | 98 | 0.160 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 85 | 0.160 |
Why?
| | Acetaldehyde | 1 | 2019 | 17 | 0.160 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 146 | 0.150 |
Why?
| | Mammary Glands, Animal | 1 | 2020 | 129 | 0.150 |
Why?
| | Nuclear Family | 1 | 2019 | 54 | 0.150 |
Why?
| | Family Characteristics | 1 | 2020 | 191 | 0.150 |
Why?
| | Lactation | 1 | 2020 | 181 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 2 | 2024 | 558 | 0.150 |
Why?
| | Immunoglobulin G | 5 | 2023 | 893 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2024 | 847 | 0.150 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 147 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2022 | 341 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.140 |
Why?
| | Mucous Membrane | 1 | 2018 | 125 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2016 | 46 | 0.130 |
Why?
| | Prevalence | 2 | 2022 | 2734 | 0.130 |
Why?
| | Plasma Cells | 1 | 2016 | 71 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2019 | 327 | 0.120 |
Why?
| | Peptides | 1 | 2021 | 985 | 0.120 |
Why?
| | Molecular Mimicry | 1 | 2014 | 42 | 0.110 |
Why?
| | Mitochondria | 1 | 2021 | 948 | 0.110 |
Why?
| | Immunoglobulin M | 3 | 2022 | 289 | 0.110 |
Why?
| | Animals | 5 | 2023 | 36940 | 0.110 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 5472 | 0.100 |
Why?
| | Mouth Mucosa | 1 | 2014 | 92 | 0.100 |
Why?
| | Mice | 4 | 2023 | 17787 | 0.100 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 12 | 0.100 |
Why?
| | Young Adult | 3 | 2021 | 13209 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 1100 | 0.090 |
Why?
| | Arthrography | 1 | 2011 | 17 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2013 | 303 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1946 | 0.090 |
Why?
| | Mass Screening | 1 | 2020 | 1287 | 0.090 |
Why?
| | Population Surveillance | 1 | 2015 | 482 | 0.090 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.090 |
Why?
| | Remission Induction | 1 | 2012 | 288 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 6763 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3295 | 0.090 |
Why?
| | Joints | 1 | 2011 | 105 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1266 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2022 | 10811 | 0.090 |
Why?
| | Time-to-Treatment | 1 | 2012 | 205 | 0.090 |
Why?
| | Blood Pressure | 1 | 2017 | 1786 | 0.080 |
Why?
| | Time Factors | 3 | 2020 | 6828 | 0.080 |
Why?
| | Air Pollution | 1 | 2013 | 316 | 0.080 |
Why?
| | Disease Susceptibility | 2 | 2021 | 347 | 0.080 |
Why?
| | Vital Capacity | 2 | 2022 | 311 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1483 | 0.070 |
Why?
| | Organ Specificity | 2 | 2019 | 305 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1242 | 0.060 |
Why?
| | Cohort Studies | 3 | 2022 | 5742 | 0.060 |
Why?
| | Switzerland | 1 | 2025 | 37 | 0.060 |
Why?
| | Family | 2 | 2021 | 671 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1509 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2828 | 0.060 |
Why?
| | Receptors, CXCR5 | 1 | 2024 | 21 | 0.060 |
Why?
| | Telomere Shortening | 1 | 2024 | 20 | 0.050 |
Why?
| | Smoking | 2 | 2024 | 1627 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 54 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.050 |
Why?
| | Rituximab | 1 | 2022 | 176 | 0.050 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 43 | 0.040 |
Why?
| | Arthralgia | 1 | 2021 | 56 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 166 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 344 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 185 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 280 | 0.040 |
Why?
| | Cytokines | 2 | 2020 | 2085 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 84 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 68 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1178 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 268 | 0.040 |
Why?
| | Prolactin | 1 | 2020 | 96 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 132 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 390 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 189 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 318 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 220 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 372 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4565 | 0.040 |
Why?
| | Methotrexate | 1 | 2020 | 260 | 0.040 |
Why?
| | Vitamin D | 1 | 2022 | 397 | 0.040 |
Why?
| | Arginine | 1 | 2020 | 271 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 622 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 138 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 521 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 625 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 460 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 465 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 500 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 904 | 0.030 |
Why?
| | Environment | 1 | 2019 | 358 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 4 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 15 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 778 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 93 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 415 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 891 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2015 | 75 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 771 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 108 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.030 |
Why?
| | Proteome | 1 | 2020 | 472 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 455 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1502 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 971 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 15657 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1325 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 171 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 531 | 0.030 |
Why?
| | Risk | 1 | 2016 | 912 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 889 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1111 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2844 | 0.030 |
Why?
| | Geographic Information Systems | 1 | 2013 | 45 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 539 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 738 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2020 | 4193 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2833 | 0.020 |
Why?
| | United States | 2 | 2022 | 14841 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 561 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2189 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3457 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1972 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 410 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3958 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2389 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 700 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 315 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 370 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2057 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2607 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 21513 | 0.010 |
Why?
|
|
Demoruelle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|